The analysis of Eribulin in patients with unresectable breast cancer, retorospective multicenter study

The analysis of Eribulin in patients with unresectable breast cancer, retorospective multicenter study - Kyoto ABC Cohort Study 01

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014158

Enrollment

150

Registered

2014-06-07

Start date

2014-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-negative Unresectable breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The patients of HER2-negative unresectable breast cancer with Eribulin treatment.

Exclusion criteria

Exclusion criteria: none.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Countries

Japan

Contacts

Public ContactTakeshi Kotake

Kobe City Medical Center General Hospital medical oncology

t-kotake@kcho.jp078-302-4321

Outcome results